Serum placental protein 14 in pre-menopausal and post-menopausal women — dependency on oestrogen/progestogen status

This publication has 14 references indexed in Scilit:

• Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.
  BMJ, 1989
• The measurement of secretory endometrial protein PP14 in serum from postmenopausal women receiving unopposed estrogen or continuously combined estrogen/ progestogen
  Gynecological Endocrinology, 1989
• Immunohistological localization of human endometrial secretory protein, 'pregnancy-associated endometrial 2-globulin' ( 2-PEG), during the menstrual cycle
  Reproduction, 1988
• The post-menopausal uterus: the effect of hormone replacement therapy on the serum levels of secretory endometrial protein PP14/β-lactoglobulin homologue
  Human Reproduction, 1987
• LUTEAL PHASE CONCENTRATIONS OF A PROGESTAGEN-ASSOCIATED ENDOMETRIAL PROTEIN (PEP) IN THE SERUM OF CYCLING WOMEN WITH ADEQUATE OR INADEQUATE ENDOMETRIUM∗
  Journal of Clinical Endocrinology & Metabolism, 1986
• Secretory Endometrium Synthesizes Placental Protein 14*
  Endocrinology, 1986
• UNCOUPLING OF BONE FORMATION AND RESORPTION BY COMBINED OESTROGEN AND PROGESTAGEN THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS
  The Lancet, 1985
• Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium
  New England Journal of Medicine, 1981
• Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal females
  European Journal of Clinical Investigation, 1980
• LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN
  The Lancet, 1976